InvestorsHub Logo
Followers 92
Posts 3703
Boards Moderated 0
Alias Born 12/21/2017

Re: BeamMeUpScotty post# 31359

Wednesday, 10/14/2020 7:51:31 AM

Wednesday, October 14, 2020 7:51:31 AM

Post# of 35961
Exactly right! From the 8k

As a result of the issuance of the Common Shares and Series F Preferred Stock, Ridgeway Therapeutics became the owner of approximately 54.14% of the Company’s issued and outstanding Common Stock. Furthermore, by virtue of the issuance of the Series F Preferred Stock, Ridgeway will vote on an as converted to common stock basis which shall be equal to eighty percent (80%) of the issued and outstanding Common Stock post-conversion. Accordingly, the board of directors of the Company has determined that a change in control of the registrant has occurred. The Company did not have a prior relationship with Ridgeway, or any of its principals, except pursuant to the terms contained in the Termination Agreement and its previous relationship under the Licensing Agreement.

The information set forth herein is qualified in its entirety by the terms contained in the Termination Agreement and COD, copies of which are attached to this report as Exhibits 10.01 and 3.01(i), respectively.

https://www.otcmarkets.com/filing/html?id=14435377&guid=kTn6UnSkhmIrc3h